Covance celebrated the grand opening of its new flagship Genomics Lab in Indianapolis, Indiana on February 14th. Co-located with its established, industry-leading Central Laboratory and Bioanalysis Lab, the site provides greater testing efficiencies and comprehensive scientific solutions to help biopharmaceutical companies develop therapies faster and with a greater probability of success.
The new Genomics Lab adds 16K ft2 of new, dedicated laboratory space to deliver applied genomics solutions from single target to whole genome analysis. The laboratory also consolidates exploratory studies and biomarker development, patient management (CAP/CLIA) laboratory testing and Companion Diagnostic (CDx) development.
The state-of-the-art lab is one of several transformative investments from Covance in genomics, anatomic pathology and histology (APH), and flow cytometry testing solutions globally. It follows the 2019 opening of the Shanghai R&D Center, a near doubling of genomics testing capacity at the Covance Geneva location, and the opening of an APH laboratory in Japan. Additional investments and enhancements in genomics testing solutions are also underway at the Covance Singapore location.
With more than 250 approved therapies having pharmacogenomic biomarkers listed in their drug labels and more than 40% of recent drug approvals classified as precision medicines, genomics and other specialty testing are an integral part of therapeutic and companion diagnostics development. With end-to-end precision medicine solutions, Covance and LabCorp provide trusted delivery and continuity in development, clinical trial support and commercialization.